Cancer Genetics Q2 Revenues Drop 17 Percent, Miss Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics today reported a 17 percent year-over-year decrease in its second quarter revenues resulting from a drop in test volumes related to its clinical trials business.

For the three months ended June 30, the Rutherford, NJ-based cancer diagnostics firm said that revenues contracted to $1.5 million from $1.8 million in the year-ago period, missing the consensus Wall Street estimate of $2.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.